Commentary: Consensus Guidelines on the Appropriate Use of Brand-Name and Generic Anti-Seizure Medication for the Management of Epilepsy in the Gulf Region
Affiliations
Affiliations
- Neurology Department, American Center for Psychiatry and Neurology, Abu Dhabi, UAE. talsaadi@live.ca.
- Neurology Department, Rashid Hospital, Dubai, UAE.
- Department of Medicine, Kuwait University, Kuwait City, Kuwait.
- Neurology Department, Khoula Hospital, Muscat, Oman.
- Neurology, Weill Cornell Medical College-Qatar (WCMC-Q), Ar-Rayyan, Qatar.
- Ibn Sina Hospital, Kuwait, Kuwait.
Abstract
Introduction: The clinical, social, and economic burden of epilepsy is undeniable. Local guidance on epilepsy management is limited and needed to address the both use of anti-seizure medication (ASM) and switching practices which influence clinical outcomes.
Areas covered: An expert panel composed of practicing neurologists and epileptologists from countries of the Gulf Cooperation Council (GCC) met in 2022 to discuss local challenges in the management of epilepsy and formulate recommendations for clinical practice. Published literature on the outcomes of ASM switching was reviewed along with clinical practice/gaps, international guidelines, and local treatment availabilities.
Expert opinion: Improper ASM use and inappropriate brand-name-to-generic or generic-to-generic switching can contribute to worsening clinical outcomes in epilepsy. ASMs should be used for the management of epilepsy based on patient clinical profile, underlying epilepsy syndrome, and drug availability to ensure optimal and sustainable treatment. Both first-generation and newer ASMs can be considered; appropriate use is recommended from the beginning of treatment. It is critical to avoid inappropriate ASM switching to avoid breakthrough seizures. All generic ASMs should fulfill strict regulatory requirements. If needed, ASM changes should always be approved by the treating physician. ASM switching (brand-name-to-generic, generic-to-generic, generic-to-brand-name) should be avoided in epilepsy patients who have achieved control but can be considered for those uncontrolled on current medication.
Keywords: Anti-seizure medication; Consensus; Drug substitution; Epilepsy; Gulf.
Conflict of interest statement
Abubaker Almadani, Jasem Al-Hashel, Abdullah Al Salti, Gayane Melikyan, and Riaz Ahmed Khan have nothing to declare. Taoufik Alsaadi has no conflicts of interest to declare. This work was not undertaken as part of his role in the Emirati League Against Epilepsy.
Similar articles
Therapeutic Basis of Generic Substitution of Antiseizure Medications.
Elmer S, Reddy DS.J Pharmacol Exp Ther. 2022 May;381(2):188-196. doi: 10.1124/jpet.121.000994. Epub 2022 Mar 3.PMID: 35241634 Free PMC article. Review.
Terman SW, Lin CC, Kerr WT, DeLott LB, Callaghan BC, Burke JF.Neurology. 2022 Jun 15;99(8):e751-61. doi: 10.1212/WNL.0000000000200779. Online ahead of print.PMID: 35705496 Free PMC article.
Asadi-Pooya AA, Patel AA, Trinka E, Mazurkiewicz-Beldzinska M, Cross JH, Welty TE.Epileptic Disord. 2022 Oct 1;24(5):751-764. doi: 10.1684/epd.2022.1468.PMID: 35894673 English.
Smith MC, Klein P, Krauss GL, Rashid S, Seiden LG, Stern JM, Rosenfeld WE.Neurol Ther. 2022 Dec;11(4):1705-1720. doi: 10.1007/s40120-022-00400-5. Epub 2022 Sep 3.PMID: 36057761 Free PMC article.
Roberti R, Casarella A, Iudice A, La Neve A, Beghi E, Capovilla G, Di Bonaventura C, Giorgi FS, Grosso S, Iannone LF, Romigi A, Specchio LM, Zaccara G, Mecarelli O, Russo E; Antiseizure Medications Commission of the Italian League against Epilepsy LICE.Epilepsy Behav. 2021 Mar;116:107804. doi: 10.1016/j.yebeh.2021.107804. Epub 2021 Feb 10.PMID: 33581599 Review.
KMEL References
References
-
- World Health Organization, International League Against Epilepsy, International Bureau for Epilepsy. Epilepsy: a public health imperative. 2019. https://www.ilae.org/files/dmfile/19053_Epilepsy_A-public-health-imperat.... Accessed 16 Oct 2022.
-
- Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) cause and risk summary. 2020. Seattle: IHME, University of Washington. https://vizhub.healthdata.org/gbd-results/. Accessed 16 Oct 2022.
-
- Abduelkarem AR. Societal problems that patients with epilepsy are facing in Sharjah, UAE. Epilepsy Behav. 2016;59:142–6. - PubMed
-
- AlHarbi FA, Alomari MS, Ghaddaf AA, et al. Public awareness and attitudes toward epilepsy in Saudi Arabia: a systematic review and meta-analysis. Epilepsy Behav. 2021;124. - PubMed
-
- Alsaadi T, El Hammasi K, Shahrour TM, et al. Prevalence of depression and anxiety among patients with epilepsy attending the epilepsy clinic at Sheikh Khalifa Medical City, UAE: a cross-sectional study. Epilepsy Behav. 2015;52:194–9. - PubMed
-
- Al-Zakwani I, Hanssens Y, Deleu D, et al. Annual direct medical cost and contributing factors to total cost of epilepsy in Oman. Seizure. 2003;12:555–60. - PubMed
-
- Begley C, Wagner RG, Abraham A, et al. The global cost of epilepsy: a systematic review and extrapolation. Epilepsia. 2022;63:892–903. - PubMed
-
- Gao L, Xia L, Pan SQ, et al. Burden of epilepsy: a prevalence-based cost of illness study of direct, indirect and intangible costs for epilepsy. Epilepsy Res. 2015;110:146–56. - PubMed
-
- Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397:1375–86. - PMC - PubMed
-
- Odi R, Franco V, Perucca E, et al. Bioequivalence and switchability of generic antiseizure medications (ASMs): a re-appraisal based on analysis of generic ASM products approved in Europe. Epilepsia. 2021;62:285–302. - PubMed
-
- Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397:1363–74. - PMC - PubMed
-
- Haddad N, Melikyan G, Al Hail H, et al. Epilepsy in Qatar: causes, treatment, and outcome. Epilepsy Behav. 2016;63:98–102. - PubMed
-
- Wilkins SS, Mesraoua B, Palomo GA, et al. Characteristics of patients with confirmed epilepsy and psychogenic nonepileptic seizures in Qatar. Epilepsy Behav. 2018;85:218–21. - PubMed
-
- Olsson P, Freij J, Compagno Strandberg M, et al. Physicians’ attitudes toward generic substitutions of antiseizure drugs in epilepsy. Acta Neurol Scand. 2021;144:600–7. - PubMed
-
- Das S, Jiang X, Jiang W, et al. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy. Epilepsy Behav. 2020;105:106936. - PubMed
-
- Barenie RE, Kesselheim AS, Gagne JJ, et al. Preferences for and experiences with pill appearance changes: national surveys of patients and pharmacists. Am J Manag Care. 2020;26:340–7. - PubMed
-
- Olsson P, Pearson K, Reimers A, et al. Widespread skeptic attitudes among people with epilepsy toward generic antiseizure drugs—a Swedish survey study. Epilepsy Behav. 2021;114. - PubMed
-
- Gha-Hyun L, Dae SJ. Brand name to generic substitution of levetiracetam in patients with epilepsy. Seizure. 2018;60:127–31. - PubMed
-
- Vari MS, Pinto F, Mencaroni E, et al. Safety of overnight switch from brand-name to generic levetiracetam. Clin Drug Investig. 2016;36:87–91. - PubMed
-
- Trimboli M, Russo E, Mumoli L, et al. Brand-to-generic levetiracetam switching: a 4-year prospective observational real-life study. Eur J Neurol. 2018;25:666–71. - PubMed
-
- Markoula S, Chatzistefanidis D, Gatzonis S, et al. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting. Seizure. 2017;48:1–6. https://pubmed.ncbi.nlm.nih.gov/28363098/. - PubMed
-
- Reimers A, Olsson P, Nilsson J, et al. Impact of generic substitution on levetiracetam serum concentration—a prospective study in an outpatient setting. Epilepsy Res. 2017;134:54–61. - PubMed
-
- Fanella M, Morano A, Fattouch J, et al. Switch from originator to equivalent drug in the era of generic antiepileptic drugs: study of Keppra Versus Epitiram clinical equivalence. Clin Neuropharmacol. 2017;40:239–42.. - PubMed
-
- Beran RG. Generic substitution and advice to patients -potential legal medicine consequences—from A (Australia) to U (United Kingdom or United States of America). Seizure. 2021;91:515–9. - PubMed
-
- Srichaiya A, Longchoopol C, Oo-Puthinan S, et al. Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study. Clin Ther. 2008;30:1844–51. - PubMed
-
- Ting TY, Jiang W, Lionberger R, et al. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard. Epilepsia. 2015;56:1415–24.. - PubMed
-
- Privitera MD, Welty TE, Gidal BE, et al. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. Lancet Neurol. 2016;15:365–72. - PubMed
-
- Lang JD, Kostev K, Reindl C, et al. Manufacturer switch of anti-seizure drugs may not increase the risk of seizure recurrence in Children: a nationwide study of prescription data in Germany. Epilepsy Behav. 2021;115. - PubMed
-
- Lang JD, Kostev K, Onugoren MD, et al. Switching the manufacturer of antiepileptic drugs is associated with higher risk of seizures: a nationwide study of prescription data in Germany. Ann Neurol. 2018;84:918–25. - PubMed
-
- Hansen RN, Nguyen HP, Sullivan SD. Bioequivalent antiepileptic drug switching and the risk of seizure-related events. Epilepsy Res. 2013;106:237–43.. - PubMed
-
- Hansen RN, Campbell JD, Sullivan SD. Association between antiepileptic drug switching and epilepsy-related events. Epilepsy Behav. 2009;15:481–5. - PubMed
-
- Zachry WM, Doan QD, Clewell JD, et al. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia. 2009;50:493–500. - PubMed
-
- Devine ST, Weisbart E, Barron J, et al. Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs. Curr Med Res Opin. 2010;26:455–63. - PubMed
-
- Erickson SC, Le L, Ramsey SD, et al. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. Epilepsia. 2011;52:1365–71. - PubMed
-
- Polard E, Nowak E, Happe A, et al. Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study. Pharmacoepidemiol Drug Saf. 2015;24:1161–9. - PubMed